Artificial Intelligence (AI) in Biopharmaceutical Market Size To Surpass USD 14.07 Bn By 2032

The global artificial intelligence (AI) in biopharmaceutical market size was valued at USD 0.86 billion in 2022 and is projected to surpass around USD 14.07 billion by 2032, expanding at a remarkable CAGR of 32.3% from 2023 to 2032.

The global artificial intelligence (AI) in biopharmaceutical market size was valued at USD 0.86 billion in 2022 and is projected to surpass around USD 14.07 billion by 2032, expanding at a remarkable CAGR of 32.3% from 2023 to 2032.

The global artificial intelligence (AI) in biopharmaceutical market size is expected to reach around USD 6.04 billion by 2029. North America has held the maximum market share of 45% in 2022.

Artificial Intelligence (AI) makes significant contributions to the biopharmaceutical industry through the use of sophisticated computational techniques and machine learning approaches. The entire drug development process—from identification to healthcare applications—is accelerated by this technology integration. Artificial Intelligence (AI) is powerful because it can quickly and efficiently analyze large biological datasets, which can help identify potential drug targets. Moreover, it enhances clinical trial design, guaranteeing efficacy and accuracy. AI is having an impact on healthcare delivery as well. Individualized treatments are being provided to patients, which is a paradigm change in medical procedures. All things considered, artificial intelligence (AI) is revolutionizing the biopharmaceutical industry by optimizing workflows and promoting medication development and patient-centered care.

Download the Sample Copy@

Key Insights:

  • In 2022, the drug discovery segment accounted for 35% of the market share. On the other hand, between 2023 and 2032, the research segment is predicted to expand at an astounding CAGR of 32.8%.
  • In 2022, the revenue share contributed by the natural language processing segment exceeded 32 percent. Over the anticipated period, the deep learning segment is anticipated to grow at the fastest CAGR.
  • In 2022, the hardware segment held the highest market share, accounting for 44% of the total. Conversely, during the anticipated period, the service category is anticipated to grow at the fastest CAGR.
  • In 2022, the cloud sector accounted for 52% of the total market share.

Growth Factors

  • Clinical Trials Optimization: By predicting patient reactions, optimizing trial protocols, and finding appropriate patient populations, artificial intelligence (AI) improves the planning and implementation of clinical trials. Clinical studies become more productive and economical as a result.
  • Supply Chain Optimization: Artificial intelligence (AI) technology helps the biopharmaceutical supply chain run more smoothly by forecasting demand, cutting down on manufacturing inefficiencies, and enhancing inventory control. This lowers costs and guarantees a more consistent supply of pharmaceuticals.
  • Regulatory Compliance: By automating compliance procedures and guaranteeing that drug development and production follow regulatory requirements, artificial intelligence (AI) systems help navigate complex regulatory environments. This lowers the possibility of regulatory problems and speeds up the approval procedure.
  • Market Expansion and Adoption: As the benefits of AI become more evident, there is a growing acceptance and adoption of AI technologies across the biopharmaceutical sector. This increased awareness and willingness to incorporate AI into various stages of drug development contribute to market growth.

Regional Stance

In 2022, North America accounted for the greatest revenue share, with 45%. For a variety of reasons, North America dominates the artificial intelligence (AI) in the pharmaceuticals sector. First off, there are large expenditures in AI research and development in the region, together with a strong healthcare infrastructure. Second, the biopharmaceutical sector in North America is flourishing, drawing in both well-established businesses and upstarts who are eager to use AI into personalized medicine and drug development.

Thirdly, innovation and talent in AI are fostered by the existence of globally recognized universities and research organizations. And last, to further cement North America’s leading position in the market, the biopharmaceutical industry is seeing a surge in the use of AI thanks to favorable funding opportunities and regulatory frameworks.

Asia-Pacific is predicted to experience the fastest rate of growth. Several key aspects support Asia-Pacific’s substantial presence in the artificial intelligence (AI) biopharmaceutical market. The biopharmaceutical industry in the area is rapidly growing and is characterized by rising investments in R&D projects. There is a strong need for AI-powered solutions due to its sizable patient population and rising healthcare costs, especially in the field of personalized medicine.

Ask Here for Customization@

Artificial Intelligence (AI) in Biopharmaceutical Market Scope

Report Coverage


Growth Rate from 2023 to 2032

CAGR of 32.3%

Market Size in 2023

USD 1.13 Billion

Market Size by 2032

USD 14.07 Billion

Largest Market

North America

Base Year


Forecast Period

2023 to 2032

Segments Covered

By Application, By Technology, By Offering, and By Deployment

Regions Covered

North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Market Drivers

Data Explosion and Analytics Demand:

AI effectively fills the requirement for advanced analytics needed to derive meaningful insights from the explosion of biomedical data. AI makes it possible for researchers to extract useful information from a variety of sources because of its ability to process large datasets. The increasing availability of clinical, proteomics, and genomes data creates a perfect environment for artificial intelligence to find trends and connections. By doing this, artificial intelligence (AI) turns into a vital tool for finding new therapeutic targets and biomarkers, which promotes advancements in drug development and biomedical research.

Accelerated Drug Discovery:

The conventional method of drug discovery is renowned for requiring a significant amount of time and resources. By quickly analysing enormous information, forecasting possible medication candidates, and optimising formulations, AI-driven platforms are changing this. This speeding up results in a large decrease in the time and expense involved in drug discovery. AI has a positive impact on the biopharmaceutical pipeline’s efficiency, which makes it a desirable option for pharmaceutical companies looking to accelerate the development of novel medicines. Artificial Intelligence (AI) is changing the pharmaceutical research and development environment by not only speeding up the drug discovery process but also providing a more economical method.

Precision Medicine Advancements:

A thorough understanding of each patient’s unique profile is essential to the shift towards personalized treatment. Finding patient-specific treatment plans is greatly aided by AI’s expertise in evaluating complex genetic and clinical data. This is in line with the industry’s goal of creating tailored medicines, which seek to reduce side effects and improve overall therapeutic effectiveness. Artificial intelligence (AI) is being used in healthcare to improve patient care by streamlining treatment customization and facilitating more accurate and effective patient-centered care.

Market Challenges

Data Quality and Standardization:

The standardization and quality of input data are critical to AI’s efficacy. AI algorithms have difficulties in the biopharmaceutical industry because to the variety of data sources, each with different formats and quality criteria. It is crucial to tackle the crucial issue of guaranteeing data precision, uniformity, and alignment among many platforms and establishments in order to optimize the effectiveness of artificial intelligence applications in this domain. To fully utilize AI in biopharmaceutical research and development, these challenges must be overcome, highlighting the significance of a consistent and unified approach to data management.

Interoperability and Integration:

Sophisticated operations in biopharmaceuticals require a lot of work to be seamlessly integrated with AI. A difficulty that requires standardizing data formats and interfaces is ensuring compatibility between different AI systems and current databases. The establishment of a unified and effective AI-driven ecosystem in the sector depends on resolving these integration obstacles. The aforementioned highlights the significance of creating uniform procedures and structures to enable the smooth integration of AI technologies with current biopharmaceutical procedures, hence enhancing workflow effectiveness and fostering innovation in the domain.

Unforeseen Legal and Liability Issues:

The ever-evolving landscape of artificial intelligence (AI) technology gives rise to legal and liability concerns that current rules could not completely understand or address. It is difficult to determine who is responsible for mistakes or unfavorable results that arise from AI algorithms, hence legal and regulatory oversight is necessary. The creation and improvement of legal frameworks that can successfully negotiate the complexities of accountability in the field of artificial intelligence is imperative as AI develops in order to ensure a fair and just resolution of any issues that may arise from its growing capabilities.

Market Trends

Advanced Drug Discovery Algorithms:

A fast-expanding trend in drug discovery is the application of sophisticated AI systems. Huge datasets are being analyzed by using deep learning networks, machine learning models, and natural language processing. therapeutic development is expedited by these tools, which help anticipate possible therapeutic candidates and optimize chemical structures. This pattern not only boosts productivity but also raises the possibility of finding new therapeutic targets, which is a major development in the use of AI in the pharmaceutical sector.

Real-time Data Analysis for Clinical Decision Support:

Real-time data analysis for clinical decision support is becoming the norm when it comes to incorporating AI into healthcare settings. Artificial intelligence (AI) algorithms examine patient data to provide timely insights to medical professionals, aiding in diagnosis, treatment planning, and patient monitoring. This tendency eventually improves patient care quality by increasing the effectiveness of healthcare delivery and fostering better informed decision-making. Healthcare could undergo a transformation thanks to AI’s real-time capabilities in clinical settings, which can help medical practitioners make decisions more quickly and accurately.

Blockchain for Data Security:

The use of blockchain technology for data security is becoming more and more popular as a result of the number of sensitive health data that is expanding. Data integrity and patient privacy are addressed by blockchain, which guarantees safe and transparent data sharing. This new development strengthens industry confidence in AI applications in the biopharmaceutical sector by offering a decentralized, safe framework for exchanging and maintaining patient data. In the context of AI-driven applications, the implementation of blockchain not only builds a trustworthy and traceable system but also reinforces data security, encouraging trust in the moral treatment of private health information.

Related Reports:

Blockchain in Healthcare Market: The global blockchain in healthcare market was valued at USD 0.76 billion in 2022 and is expected to hit USD 14.25 billion by 2032, growing at a compound annual growth rate (CAGR) of 34.02% from 2023 to 2032.

Biopharmaceutical Third Party Logistics Market: The global biopharmaceutical third party logistics market size was exhibited at USD 110 billion in 2022 and it is expected to expand to around USD 192.39 billion by 2032, poised to grow at a CAGR of 5.80% during the forecast period 2023 to 2032.

Biopharmaceutical CMO and CRO Market: The global biopharmaceutical CMO and CRO market size was valued at USD 34 billion in 2022 and is expected to hit over USD 62.93 billion by 2032 and growing at a CAGR of 6.4% from 2023 to 2032.

You can place an order or ask any questions, please feel free to contact at | +1 650 460 3308

Recent Developments

  • Insilico Medicine revealed in July 2023 that it had discovered a new treatment option for Alzheimer’s disease through its AI-powered drug discovery platform.
  • Eli Lilly & Company and BenevolentAI teamed together in August 2023 to take advantage of BenevolentAI’s AI platform in order to find novel targets for drugs and provide cutting-edge treatments for neurodegenerative illnesses.
  • Verily and Otsuka established a partnership in February 2023 to create cutting-edge techniques for clinical trials utilising AI to enhance patient outcomes in Major Depressive Disorder (MDD) trials.
  • Exscientia PLC and Charité - Universitätsmedizin Berlin (Germany) teamed together in March 2023 to introduce Exscientia’s AI-powered precision medicine platform for the treatment of haematological malignancies.

Market Key Players:

  • IBM Watson Health
  • Google Health
  • NVIDIA Corporation
  • Microsoft Healthcare
  • DeepMind
  • Atomwise
  • Insilico Medicine
  • PathAI
  • Tempus
  • GNS Healthcare
  • Cloud Pharmaceuticals
  • Numerate
  • Recursion Pharmaceuticals
  • Healx

Market Segmentation

By Application

  • Drug Discovery
  • Precision Medicine
  • Medical Imaging & Diagnostics
  • Research

By Technology

  • Machine Learning
  • Natural Language Processing
  • Deep Learning
  • Others

By Offering

  • Hardware
  • Software
  • Services

By Deployment

  • Cloud
  • On-Premises

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Browse Table of Contents:

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Immediate Delivery Available | Buy This Premium Research Report@

Unlocking Market Insights through Data Excellence

The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.

Access our Premium Real Time Data Intelligence Tool, Visit:

About Us

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Our Blogs:

For Latest Update Follow Us:

Linkedin | Facebook | Twitter